The Hidden Inflammation Problem Most People Never Notice

Inflammation in its acute form is a precise and necessary defence. Chronic low-grade inflammation is a different phenomenon entirely: a silent, sustained immune activation that produces no obvious symptoms but contributes substantially to virtually every major chronic disease of modern life.

High-sensitivity C-reactive protein, IL-6, TNF-alpha and ferritin are among the most widely studied markers of low-grade inflammation. Modest elevations within the conventional reference range still predict elevated cardiovascular and metabolic risk in large prospective cohorts.

Inflammation and oxidative stress reinforce one another. Reactive oxygen species damage cellular components, triggering further inflammatory signalling, which in turn produces more reactive oxygen species. Interrupting this cycle is a central goal of mitochondrial and metabolic interventions.

The term 'inflammaging' was coined to describe the progressive low-grade inflammatory state observed in older adults. It is associated with sarcopenia, cognitive decline, frailty and overall mortality risk. Interventions that reduce inflammaging are an active area of longevity research.

Visceral adipose tissue is itself an inflammatory organ, secreting cytokines that interfere with insulin signalling in distant tissues. This is one mechanism by which body composition matters more for metabolic health than body weight alone.

Clinical trials of berberine consistently show reductions in high-sensitivity C-reactive protein and other inflammatory markers. The mechanism appears to involve both direct effects on inflammatory signalling pathways and indirect effects via gut microbiome modulation and improved glucose handling — each of which reduces upstream inflammatory drivers.